Back to Search Start Over

Adiposity and Endometrial Cancer Risk in Postmenopausal Women: A Sequential Causal Mediation Analysis

Authors :
Dashti, SG
English, DR
Simpson, JA
Karahalios, A
Moreno-Betancur, M
Biessy, C
Rinaldi, S
Ferrari, P
Tjonneland, A
Halkjaer, J
Dahm, CC
Vistisen, HT
Menegaux, F
Perduca, V
Severi, G
Aleksandrova, K
Schulze, MB
Masala, G
Sieri, S
Tumino, R
Macciotta, A
Panico, S
Hiensch, AE
May, AM
Quiros, JR
Agudo, A
Sanchez, M-J
Amiano, P
Colorado-Yohar, S
Ardanaz, E
Allen, NE
Weiderpass, E
Fortner, RT
Christakoudi, S
Tsilidis, KK
Riboli, E
Kaaks, R
Gunter, MJ
Viallon, V
Dossus, L
Dashti, SG
English, DR
Simpson, JA
Karahalios, A
Moreno-Betancur, M
Biessy, C
Rinaldi, S
Ferrari, P
Tjonneland, A
Halkjaer, J
Dahm, CC
Vistisen, HT
Menegaux, F
Perduca, V
Severi, G
Aleksandrova, K
Schulze, MB
Masala, G
Sieri, S
Tumino, R
Macciotta, A
Panico, S
Hiensch, AE
May, AM
Quiros, JR
Agudo, A
Sanchez, M-J
Amiano, P
Colorado-Yohar, S
Ardanaz, E
Allen, NE
Weiderpass, E
Fortner, RT
Christakoudi, S
Tsilidis, KK
Riboli, E
Kaaks, R
Gunter, MJ
Viallon, V
Dossus, L
Publication Year :
2021

Abstract

BACKGROUND: Adiposity increases endometrial cancer risk, possibly through inflammation, hyperinsulinemia, and increasing estrogens. We aimed to quantify the mediating effects of adiponectin (anti-inflammatory adipocytokine); IL6, IL1-receptor antagonist, TNF receptor 1 and 2, and C-reactive protein (inflammatory status biomarkers); C-peptide (hyperinsulinemia biomarker); and free estradiol and estrone (estrogen biomarkers) in the adiposity-endometrial cancer link in postmenopausal women. METHODS: We used data from a case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC). Eligible women did not have cancer, hysterectomy, and diabetes; did not use oral contraceptives or hormone therapy; and were postmenopausal at recruitment. Mediating pathways from adiposity to endometrial cancer were investigated by estimating natural indirect (NIE) and direct (NDE) effects using sequential mediation analysis. RESULTS: The study included 163 cases and 306 controls. The adjusted OR for endometrial cancer for body mass index (BMI) ≥30 versus ≥18.5-<25 kg/m2 was 2.51 (95% confidence interval, 1.26-5.02). The ORsNIE were 1.95 (1.01-3.74) through all biomarkers [72% proportion mediated (PM)] decomposed as: 1.35 (1.06-1.73) through pathways originating with adiponectin (33% PM); 1.13 (0.71-1.80) through inflammation beyond (the potential influence of) adiponectin (13% PM); 1.05 (0.88-1.24) through C-peptide beyond adiponectin and inflammation (5% PM); and 1.22 (0.89-1.67) through estrogens beyond preceding biomarkers (21% PM). The ORNDE not through biomarkers was 1.29 (0.54-3.09). Waist circumference gave similar results. CONCLUSIONS: Reduced adiponectin and increased inflammatory biomarkers, C-peptide, and estrogens mediated approximately 70% of increased odds of endometrial cancer in women with obesity versus normal weight. IMPACT: If replicated, these results could have implications for identifying targets for intervention to reduce endometria

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1315730063
Document Type :
Electronic Resource